Skip to main content

Advertisement

Springer Nature Link
Log in

The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS

  • Short Communication
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

It is aimed to determine expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), CD163 and CD14 in diffuse large B-cell lymphomas (DLBCL), and whether these markers may predict prognosis in DLBCL cases. A total of 52 nodal DLBCL, NOS cases with no known extranodal involvement at the time of diagnosis were evaluated. PD-1, PD-L1, CD163, and CD14 were studied by immunohistochemistry. The relationships between the results and clinical and laboratory prognostic markers were investigated. It was observed that patients with PD-1 expression < 5 positive cells/HPF had worse overall survival. No significant relationship was found between survival and PD-L1, CD163 and CD14 expressions. In addition, cases that are > 60 years of age, that have Eastern Cooperative Oncology Group (ECOG) performance score ≥ 2, stage IV disease, high International Prognostic Index score score (≥ 3), elevation of LDH, low albumin level, low hemoglobin level, low peripheral blood lymphocyte count, high peripheral blood neutrophil/lymphocyte ratio, high peripheral blood platelet/lymphocyte ratio were found to have worse overall survival. It was concluded that in patients with low number of PD-1 positive tumor-infiltrating lymphocytes have low survival rates and therefore PD-1 expression may be useful in indicating prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M et al (2017) Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget 8(3):5414–5425. https://doi.org/10.18632/oncotarget.14289

    Article  PubMed  Google Scholar 

  2. Hunt KE, Reichard KK (2008) Diffuse large B-cell lymphoma. Arch Pathol Lab Med 132(1):118–124. https://doi.org/10.5858/2008-132-118-DLBL

    Article  PubMed  Google Scholar 

  3. Zhou S, Xu L, Ma Y, Tang L, Zhang Y, Shi Y et al (2017) Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma. Oncotarget 8(12):19556–19565. https://doi.org/10.18632/oncotarget.14700

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R (2016) Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 34(4):184–192. https://doi.org/10.1002/hon.2233

    Article  CAS  PubMed  Google Scholar 

  5. Wang S, Ma Y, Sun L, Shi Y, Jiang S, Yu K et al (2018) Prognostic significance of pretreatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with diffuse large B-Cell lymphoma. Biomed Res Int 2018:9651254. https://doi.org/10.1155/2018/9651254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ahearne MJ, Bhuller K, Hew R, Ibrahim H, Naresh K, Wagner SD (2014) Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. Virchows Arch 465(3):351–358. https://doi.org/10.1007/s00428-014-1615-5

    Article  CAS  PubMed  Google Scholar 

  7. Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH et al (2016) Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B-cell lymphomas. Histopathology 68(7):1079–1089. https://doi.org/10.1111/his.12882

    Article  PubMed  Google Scholar 

  8. Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S et al (2017) The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine 96(15):e6398. https://doi.org/10.1097/md.0000000000006398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D et al (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193–2201. https://doi.org/10.1182/blood-2015-02-629600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dong L, Lv H, Li W, Song Z, Li L, Zhou S et al (2016) Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget 7(22):33350–33362. https://doi.org/10.18632/oncotarget.9061

    Article  PubMed  PubMed Central  Google Scholar 

  11. Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA et al (2016) PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 7(37):59976–59986. https://doi.org/10.18632/oncotarget.11045

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ et al (2017) Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B-cell lymphoma: a retrospective study. Chin J Cancer 36(1):94. https://doi.org/10.1186/s40880-017-0262-z

    Article  PubMed  PubMed Central  Google Scholar 

  13. Matsuki E, Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A et al (2018) Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab. Appl Immunohistochem Mol Morphol AIMM. https://doi.org/10.1097/pai.0000000000000645

    Article  Google Scholar 

  14. Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW et al (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55(11):2466–2476. https://doi.org/10.3109/10428194.2013.879713

    Article  CAS  PubMed  Google Scholar 

  15. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J et al (2006) CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol 37(1):68–77. https://doi.org/10.1016/j.humpath.2005.09.016

    Article  CAS  PubMed  Google Scholar 

  16. Khalifa KA, Badawy HM, Radwan WM, Shehata MA, Bassuoni MA (2014) CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-hodgkin lymphoma. Int J Lab Hematol 36(6):650–655. https://doi.org/10.1111/ijlh.12203

    Article  CAS  PubMed  Google Scholar 

  17. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB (2011) Immunosuppressive CD14+ HLA-DRlow/− monocytes in B-cell non-hodgkin lymphoma. Blood 117(3):872–881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shi Y, Deng L, Song Y, Lin D, Lai Y, Zhou L et al (2018) CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. Int J Hematol 108(3):254–266. https://doi.org/10.1007/s12185-018-2466-7

    Article  CAS  PubMed  Google Scholar 

  19. Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y et al (2012) Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka lymphoma study group. Histopathology 60(2):313–319. https://doi.org/10.1111/j.1365-2559.2011.04096.x

    Article  PubMed  Google Scholar 

  20. Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E et al (2015) High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33(2):110–112. https://doi.org/10.1002/hon.2142

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the Scientific Research Project Office of Manisa Celal Bayar University. Project Number: 2017-199.

Author information

Authors and Affiliations

  1. Department of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey

    Ömer Atmış, Nalan Neşe, Hanife Seda Mavili & Aydın İşisağ

  2. Department of Hematology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey

    İsmet Aydoğdu & İlknur Alaca

Authors
  1. Ömer Atmış
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Nalan Neşe
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. İsmet Aydoğdu
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. İlknur Alaca
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Hanife Seda Mavili
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Aydın İşisağ
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Ömer Atmış.

Ethics declarations

Conflict of interest

There are no conflicts of interest to declare.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Ethical Approval

The study was approved by the institutional ethic committee (Date: 11.10.2017, Reference No: 20478486-050).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atmış, Ö., Neşe, N., Aydoğdu, İ. et al. The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS. Indian J Hematol Blood Transfus 40, 340–345 (2024). https://doi.org/10.1007/s12288-023-01667-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-023-01667-w

Keywords